Dr. Xiaojia Wang 王晓稼
Chief Physician
Department of Medical Oncology (Breast Cancer), Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical management of breast cancer and solid tumors, including chemotherapy, endocrine therapy, and biological targeted therapy.
Dr. Wang holds a PhD in Oncology from Zhejiang University (2002) and completed training at the University of Pennsylvania (2007). As Chief of Breast Medical Oncology at Zhejiang Cancer Hospital, Dr. Wang serves as principal investigator for over 30 clinical trials involving drugs such as trastuzumab, lapatinib, and pertuzumab. Research interests include gene polymorphisms in endocrine therapy and tumor angiogenesis.
Professional roles
- Standing Committee Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Breast Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Chair, Medical Oncology Professional Committee, Zhejiang Anti-Cancer Association
- President, Precision Medicine Branch, Zhejiang Translational Medicine Association
Name order: in Chinese the family name comes first (Wang Xiaojia). Papers usually list the name as Xiaojia Wang or Wang X.
Selected publications
208 papers on PubMed matched by name and affiliation; 33 as first or senior author since 2016. Most recent first- or senior-author papers:
- Target Oncol, 2026 (first author): Imlunestrant as Monotherapy or in Combination with Abemaciclib in ER+, HER2- Advanced Breast Cancer: Chinese Subgroup Analysis of the Phase III Randomized EMBER-3 Study. PubMed 43002362
- Discov Oncol, 2025 (senior author): Advances in mRNA vaccine therapy for breast cancer research. PubMed 40327249
- Biotechnol Bioeng, 2025 (senior author): Application and progress of 3D tumor models in breast cancer. PubMed 39402769
- Discov Oncol, 2024 (senior author): Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer. PubMed 39729236
- Cancer Cell Int, 2024 (senior author): STAT3: Key targets of growth-promoting receptor positive breast cancer. PubMed 39468521
- Transl Breast Cancer Res, 2024 (senior author): A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer. PubMed 39184926
- Breast Cancer, 2024 (senior author): PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. PubMed 38630392
- Cancer, 2024 (senior author): Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment. PubMed 38482921
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion